Novo Nordisk plans to invest $4.1 billion in another U.S. factory, plowing more money into its biggest market amid rising discontent there over the cost of its obesity and diabetes drugs.
The project in Clayton, North Carolina, will double the company’s production footprint in the U.S., adding 1.4 million square feet of space for the final stages of manufacturing in which Novo’s medicines are filled into injector pens and prepared for consumers. The facility will add 1,000 jobs, the Danish drugmaker said Monday.
